
In pooled CORALreef data, patients with eGFR below 60 had a 65.9% placebo-adjusted LDL-C reduction at week 24, with safety comparable to placebo.
Christopher Betz, PharmD, BCPS, FKSHP, FASHP, explains how health-system pharmacists can be involved in the management of ACS patients throughout the continuum of care.
Christopher Betz, PharmD, BCPS, FKSHP, FASHP, explains how health-system pharmacists can be involved in the management of ACS patients throughout the continuum of care.






